R&D Costs, Rx Prices, and the Formula for Success in Life Sciences Innovation, With Stephen Ezell

The United States is the leader in life sciences innovation, but
that has not always been the case. As global competition
intensifies, it needs to continue spurring investment in R&D
to stay on top. Rob and Jackie sat down with Stephen Ezell, vice
president of global innovation policy at ITIF, to discuss the
history of U.S. life sciences innovation and break down R&D
costs versus the market prices of innovative
biopharmaceuticals.

Mentioned


Anusuya Chatterjee and Ross C. DeVol, “Estimating Long-Term
Economic Returns of NIH Funding on Output in the Biosciences”
(Milken Institute, 2012), 4.



Related


Rob Atkinson and Stephen Ezell, “Five Fatal Flaws in Rep.
Katie Porter’s Indictment of the U.S. Drug Industry” (ITIF, May
2021).

Joe Kennedy, “The Link Between Drug Prices and Research on
the Next Generation of Cures” (ITIF, September 2019).

Event, “How Intellectual Property Has Played a Pivotal Role
in the Global COVID-19 Response,” (ITIF, April 2021).